AI ECG Analysis segmentation by application delineates four primary use‑cases: clinical diagnosis, remote patient monitoring, drug development, and academic research. Clinical diagnosis remains the dominant driver, accounting for roughly 45 % of total revenue, as hospitals integrate AI‑enabled ECG interpretation to accelerate arrhythmia detection and reduce physician workload. Remote monitoring contributes about 30 % of the market, fueled by tele‑health platforms that transmit ECG data from wearable sensors to cloud‑based AI engines for continuous risk stratification. Drug development captures 15 % of the market; pharmaceutical firms employ AI ECG analysis to identify cardiotoxicity signals early in clinical trials, shortening development cycles. Finally, research represents the remaining 10 %, where universities and research institutes use open‑source AI models to explore novel biomarkers. Collectively, these application segments define the overall AI ECG Analysis market size, with each sub‑segment’s growth linked to regulatory acceptance, reimbursement policies, and technology adoption rates. These dynamics also influence vendor positioning and capital allocation across the ecosystem.